1-3 of 3
dyskeratosis congenita
Close
Sort by
Journal Articles

Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita

Siddharth Shukla, Ho-Chang Jeong, Christopher M. Sturgeon, Roy Parker, Luis Francisco Zirnberger Batista
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2717–2722.
https://doi.org/10.1182/bloodadvances.2020001848
Published: 2020
Includes: Supplemental data
Journal Articles

Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita

Clinical Trials & Observations
Payal P. Khincha, Alison A. Bertuch, Shahinaz M. Gadalla, Neelam Giri, Blanche P. Alter, Sharon A. Savage
Journal: Blood Advances
Blood Adv (2018) 2 (11): 1243–1249.
https://doi.org/10.1182/bloodadvances.2018016964
Published: 2018
Journal Articles

Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms

Judith C. W. Marsh, Fernanda Gutierrez-Rodrigues, James Cooper, Jie Jiang, Shreyans Gandhi, Sachiko Kajigaya, Xingmin Feng, Maria del Pilar F. Ibanez, Flávia S. Donaires, João P. Lopes da Silva, Zejuan Li, Soma Das, Maria Ibanez, Alexander E. Smith, Nicholas Lea, Steven Best, Robin Ireland, Austin G. Kulasekararaj, Donal P. McLornan, Anthony Pagliuca, Isabelle Callebaut, Neal S. Young, Rodrigo T. Calado, Danielle M. Townsley, Ghulam J Mufti
Journal: Blood Advances
Blood Adv (2018) 2 (1): 36–48.
https://doi.org/10.1182/bloodadvances.2017008110
Published: 2018
Includes: Supplemental data